Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response
Braden Waters(Queen's University), David Lillicrap(Queen's University), Andrea Labelle(Queen's University), Rouzbeh Chegeni(Queen's University), Christine Hough(Queen's University), Erin Burnett(Queen's University), Patrick Thompson(Queen's University), Mohammad Qadura(St. Michael's Hospital)
Cited by 82
Related Papers
Concise Review: Cell Therapy for Critical Limb Ischemia: An Integrated Review of Preclinical and Clinical Studies
|Stem Cells|2017|205
Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice
|Blood|2009|63
Serum Metabolic Signatures of Chronic Limb-Threatening Ischemia in Patients with Peripheral Artery Disease
|Journal of Clinical Medicine|2020|62
Endothelial-specific Loss of IFT88 Promotes Endothelial-to-Mesenchymal Transition and Exacerbates Bleomycin-induced Pulmonary Fibrosis
|Scientific Reports|2020|57
Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells
|Journal of Thrombosis and Haemostasis|2008|42